BioTelemetry Inc (NASDAQ:BEAT) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $80.33.
BEAT has been the topic of a number of recent research reports. BidaskClub upgraded BioTelemetry from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 11th. Zacks Investment Research lowered BioTelemetry from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. ValuEngine raised BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Sidoti set a $95.00 target price on BioTelemetry and gave the company a “buy” rating in a report on Tuesday, February 5th. Finally, Lake Street Capital set a $90.00 target price on BioTelemetry and gave the company a “buy” rating in a report on Friday, February 22nd.
In other BioTelemetry news, VP Heather C. Getz sold 93,383 shares of the firm’s stock in a transaction on Tuesday, January 29th. The stock was sold at an average price of $70.06, for a total value of $6,542,412.98. Following the sale, the vice president now owns 119,085 shares of the company’s stock, valued at approximately $8,343,095.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Heather C. Getz sold 64,989 shares of the firm’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $70.09, for a total value of $4,555,079.01. Following the completion of the sale, the chief financial officer now directly owns 119,085 shares in the company, valued at approximately $8,346,667.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 168,962 shares of company stock worth $11,843,134. Company insiders own 6.50% of the company’s stock.
Several hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. boosted its holdings in shares of BioTelemetry by 40.2% during the 1st quarter. Meeder Asset Management Inc. now owns 2,491 shares of the medical research company’s stock valued at $154,000 after acquiring an additional 714 shares in the last quarter. Hodges Capital Management Inc. boosted its holdings in shares of BioTelemetry by 32.7% during the 1st quarter. Hodges Capital Management Inc. now owns 46,285 shares of the medical research company’s stock valued at $2,898,000 after acquiring an additional 11,415 shares in the last quarter. Ropes Wealth Advisors LLC acquired a new stake in shares of BioTelemetry during the 1st quarter valued at $50,000. Sciencast Management LP acquired a new stake in shares of BioTelemetry during the 1st quarter valued at $611,000. Finally, First Financial Corp IN acquired a new stake in shares of BioTelemetry during the 1st quarter valued at $63,000. 88.51% of the stock is currently owned by hedge funds and other institutional investors.
BioTelemetry stock traded up $0.25 during mid-day trading on Monday, reaching $55.38. 503,100 shares of the company were exchanged, compared to its average volume of 646,033. BioTelemetry has a 12 month low of $32.65 and a 12 month high of $80.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81. The firm has a market cap of $1.86 billion, a PE ratio of 28.55 and a beta of 1.43.
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.13. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. The firm had revenue of $103.60 million for the quarter, compared to analyst estimates of $102.84 million. During the same quarter last year, the company earned $0.32 EPS. The company’s revenue was up 13.0% on a year-over-year basis. Sell-side analysts expect that BioTelemetry will post 1.94 earnings per share for the current fiscal year.
BioTelemetry Company Profile
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.